References
- Ajayi FO, Sun H, Perry J. (2000). Adverse drug reactions: a review of relevant factors. J Clin Pharmacol 40:1093–101
- Andersson T, Lundborg P, Regardh CG. (1991). Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol. Eur J Clin Pharmacol 40:61–5
- Bjornsson TD, Callaghan JT, Einolf HJ, et al. (2003). The conduct of in vitro and in vivo drug--drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32
- Blanchard N, Richert L, Coassolo P, Lave T. (2004). Qualitative and quantitative assessment of drug--drug interaction potential in man, based on Ki, IC50 and inhibitor concentration. Curr Drug Metab 5:147–56
- Bowles SK, Reeves RA, Cardozo L, Edwards DJ. (1993). Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine. J Clin Pharmacol 33:727–31
- Brown HS, Galetin A, Hallifax D, Houston JB. (2006). Prediction of in vivo drug--drug interactions from in vitro data: factors affecting prototypic drug--drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45:1035–50
- Brown HS, Ito K, Galetin A, Houston JB. (2005). Prediction of in vivo drug--drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508–18
- Cheng Y, Prusoff WH. (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–108
- Davit B, Reynolds K, Yuan R, et al. (1999). FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug--drug interactions: impact on labeling. J Clin Pharmacol 39:899–910
- Draft Food and Drug Administration Guidance for Industry. (2012). Drug interaction studies. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
- Einolf HJ. (2007). Comparison of different approaches to predict metabolic drug--drug interactions. Xenobiotica 37:1257–94
- Fleishaker JC, Hulst LK. (1994). A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46:35–9
- Foti RS, Wienkers LC, Wahlstrom JL. (2010). Application of cytochrome P450 drug interaction screening in drug discovery. Comb Chem High Throughput Screen 13:145–58
- Galetin A, Hinton LK, Burt H, et al. (2007). Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug--drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 8:685–93
- Gillette JR, Pang KS. (1977). Theoretic aspects of pharmacokinetic drug interactions. Clin Pharmacol Ther 22:623–39
- Grime K, Riley RJ. (2006). The impact of in vitro binding on in vitro--in vivo extrapolations, projections of metabolic clearance and clinical drug--drug interactions. Curr Drug Metab 7:251–64
- Gupta S, Banfield C, Kantesaria B, et al. (2004). Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J Clin Pharmacol 44:1252–9
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill
- Hinton LK, Galetin A, Houston JB. (2008). Multiple inhibition mechanisms and prediction of drug--drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res 25:1063–74
- Hoglund P, Nilsson LG. (1989). Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers. Ther Drug Monit 11:543–50
- Huang YC, Colaizzi JL, Bierman RH, et al. (1986). Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 30:206–10
- Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in vivo drug--drug interactions from in vitro data. Br J Clin Pharmacol 57:473–86
- Ito K, Chiba K, Horikawa M, et al. (2002). Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 4:E25
- Ito K, Hallifax D, Obach RS, Houston JB. (2005). Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug--drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837–44
- Ito K, Iwatsubo T, Kanamitsu S, et al. (1998). Prediction of pharmacokinetic alterations caused by drug--drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387–412
- Jaakkola T, Backman JT, Neuvonen M, et al. (2006). Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. Eur J Clin Pharmacol 62:503–9
- Kang BC, Yang CQ, Cho HK, et al. (2002). Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharmaceut Drug Dispos 23:77–81
- Karonen T, Filppula A, Laitila J, et al. (2010). Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther 88:223–30
- Karonen T, Laitila J, Niemi M, et al. (2012). Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. Eur J Clin Pharmacol 68:681–8
- Kato M, Chiba K, Hisaka A, et al. (2003). The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18:365–72
- Kees F, Holstege A, Ittner KP, et al. (2000). Pharmacokinetic interaction between proton pump inhibitors and roxithromycin in volunteers. Aliment Pharmacol Ther 14:407–12
- Kim KA, Park PW, Kim KR, Park JY. (2007). Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans. Br J Clin Pharmacol 63:339–45
- Kosugi Y, Hirabayashi H, Igari T, et al. (2012). Evaluation of cytochrome P450-mediated drug--drug interactions based on the strategies recommended by regulatory authorities. Xenobiotica 42:127–38
- Kusama M, Maeda K, Chiba K, et al. (2009). Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data. Pharm Res 26:822–35
- Lu C, Hatsis P, Berg C, et al. (2008). Prediction of pharmacokinetic drug--drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro--in vivo correlation with ketoconazole. Drug Metab Dispos 36:1255–60
- Lu C, Miwa GT, Prakash SR, et al. (2006). A novel model for the prediction of drug--drug interactions in humans based on in vitro cytochrome p450 phenotypic data. Drug Metabol Dispos 35:79–85
- Lundahl J, Regardh CG, Edgar B, Johnsson G. (1995). Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol 49:61–7
- Madsen JK, Jensen JD, Jensen LW, Pedersen EB. (1996). Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol 50:203–8
- Mao J, Mohutsky MA, Harrelson JP, et al. (2011). Prediction of CYP3A mediated drug--drug interactions using human hepatocytes suspended in human plasma. Drug Metabol Dispos 39:591--602
- Mao J, Mohutsky M, Harrelson J, et al. (2012). Predictions of CYP-mediated drug--drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos 40:706--16
- Margolis JM, Obach RS. (2003). Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 31:606–11
- McGinnity DF. (2005). Prediction of Cyp2c9-mediated drug--drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 33:1700–7
- McGinnity DF, Waters NJ, Tucker J, Riley RJ. (2008). Integrated in Vitro analysis for the in vivo prediction of cytochrome p450-mediated drug--drug interactions. Drug Metab Dispos 36:1126–34
- Muirhead M, Bochner F, Somogyi A. (1988). Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption. J Pharmacol Exp Ther 244:734–9
- Niemi M, Backman JT, Neuvonen PJ. (2004). Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 76:239–49
- Obach RS. (2005). The utility of in vitro cytochrome p450 inhibition data in the prediction of drug–drug interactions. J Pharmacol Exp Therapeut 316:336–48
- Obach RS, Lombardo F, Waters NJ. (2008a). Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385–405
- Obach RS, Lombardo F, Waters NJ. (2008b). Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385–405
- Obach RS, Walsky RL, Venkatakrishnan K, et al. (2005). In vitro cytochrome P450 inhibition data and the prediction of drug–drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582–92
- Obach RS, Walsky RL, Venkatakrishnan K, et al. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. J Pharmacol Exp Ther 316:336–48
- Rioux N, Batonga J, Colombo F, et al. (2013). A simplified approach to predict CYP3A-mediated drug–drug interactions at early drug discovery: validation with clinical data. Xenobiotica 43:592–7
- Sennef C, Timmer CJ, Sitsen JMA. (2003). Mirtazapine in combination with amitriptyline: a drug–drug interaction study in healthy subjects. Hum Psychopharmacol: Clin Exp 18:91–101
- Shibata Y, Takahashi H, Chiba M, Ishii Y. (2008). A novel approach to the prediction of drug–drug interactions in humans based on the serum incubation method. Drug Metab Pharmacokinet 23:328–39
- Shoaf SE, Elizari MV, Wang Z, et al. (2005). Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J Cardiovasc Pharmacol Ther 10:165–71
- Smith SR, Kendall MJ, Lobo J, et al. (1987). Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration. Br J Clin Pharmacol 23:311–15
- Sommers DK, Kovarik JM, Meyer EC, et al. (1993). Effects of diclofenac on isradipine pharmacokinetics and platelet aggregation in volunteers. Eur J Clin Pharmacol 44:391–3
- Spina E, Pollicino AM, Avenoso A, et al. (1993). Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15:243–6
- Stass H, Nagelschmitz J, Moeller JG, Delesen H. (2004). Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. Int J Clin Pharmacol Ther 42:23–9
- Sugita O, Sawada Y, Sugiyama Y, et al. (1981). Prediction of drug–drug interaction from in vitro plasma protein binding and metabolism. A study of tolbutamide-sulfonamide interaction in rats. Biochem Pharmacol 30:3347–54
- Tachibana T, Kato M, Watanabe T, et al. (2009). Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 39:430–43
- Takahashi H, Sato T, Shimoyama Y, et al. (1999). Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther 66:569–81
- Tateishi T, Nakashima H, Shitou T, et al. (1989). Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. Eur J Clin Pharmacol 36:67–70
- Tornio A, Niemi M, Neuvonen PJ, Backman JT. (2008). Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 36:73–80
- Tran TH, Von Moltke LL, Venkatakrishnan K, et al. (2002). Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 30:1441–5
- Transon C, Leemann T, Vogt N, Dayer P. (1995). In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 58:412–7
- Tucker GT, Houston JB, Huang SM. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther 70:103–14
- Turpeinen M, Korhonen LE, Tolonen A, et al. (2006). Cytochrome P450 (CYP) inhibition screening: comparison of three tests. Eur J Pharm Sci 29:130–8
- Ueda N, Yoshimura R, Umene-Nakano W, et al. (2009). Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. World J Biol Psychiatry 10:832–5
- Wagner F, Kalusche D, Trenk D, et al. (1987). Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol 24:213–20
- Walsky RL, Gaman EA, Obach RS. (2005). Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68–78